Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
New drug holds potential for treating advanced mastocytosis

New drug holds potential for treating advanced mastocytosis

Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too. [More]
Blood cancer treatment linked to distinct increase in molecular age of immune cells

Blood cancer treatment linked to distinct increase in molecular age of immune cells

Certain cancer treatments are known to take a toll on patients, causing side effects like fatigue, nausea and hair loss. Now, scientists are investigating whether some treatments can cause another long-term side effect: premature aging of important disease-fighting cells. [More]
Researchers find new way for early prediction of leukemic relapse

Researchers find new way for early prediction of leukemic relapse

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA-based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia (sAML), a particularly problematic disease that typically afflicts older patients who have often already experienced a bout with cancer. [More]
Protein complex could play key role in natural development of stem cells into healthy blood cells

Protein complex could play key role in natural development of stem cells into healthy blood cells

A group of proteins best known for helping to activate all mammalian genes has been found to play a particularly commanding role in the natural development of specialized stem cells into healthy blood cells, a process known as hematopoiesis. [More]
Stem cells derived from bone marrow provide better quality of life to transplant patients

Stem cells derived from bone marrow provide better quality of life to transplant patients

A large, nationwide study published in the journal JAMA Oncology found that people who received transplants of cells collected from a donor's bone marrow the original source for blood stem cell transplants, developed decades ago had better self-reported psychological well-being, experienced fewer symptoms of a common post-transplant side effect called graft-vs.-host disease and were more likely to be back at work five years after transplantation than those whose transplanted cells were taken from the donor's bloodstream. [More]
German scientists develop new approach to prevent GvHD after bone marrow transplants

German scientists develop new approach to prevent GvHD after bone marrow transplants

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants. [More]
FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). [More]
BCL-2 inhibitor shows promise in AML patients

BCL-2 inhibitor shows promise in AML patients

Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data. [More]
Scientists find new functions of ANG protein that plays key role in regulation of blood cell formation

Scientists find new functions of ANG protein that plays key role in regulation of blood cell formation

Tufts Medical Center and Tufts University scientists have found exciting, new functions of the protein angiogenin that play a significant role in the regulation of blood cell formation, important in bone marrow transplantation and recovery from radiation-induced bone marrow failure. [More]
USC researchers discover two Zika proteins potentially responsible for microcephaly

USC researchers discover two Zika proteins potentially responsible for microcephaly

USC researchers have tracked down two Zika proteins potentially responsible for thousands of microcephaly cases in Brazil and elsewhere — taking one small step toward preventing Zika-infected mothers from birthing babies with abnormally small heads. [More]
New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

Johns Hopkins researchers say they have identified a new disease gene that, when mutated, appears to increase the risk in a small number of people of developing emphysema and a lung-scarring condition known as pulmonary fibrosis. [More]
New class of anti-cancer agents may be promising treatment for multiple myeloma

New class of anti-cancer agents may be promising treatment for multiple myeloma

Australian researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma, an incurable bone marrow cancer. [More]
Scientists identify new way to impair tumour growth in lung cancer

Scientists identify new way to impair tumour growth in lung cancer

Researchers from the Cancer Science Institute of Singapore at the National University of Singapore, in collaboration with Harvard Stem Cell Institute, have discovered a new way in which the development of lung cancer can be stopped. [More]
Research could help develop better therapies for new subtype of adenocarcinoma  patients

Research could help develop better therapies for new subtype of adenocarcinoma patients

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. [More]
Advanced Instruments launches novel GloCyte System at 68th AACC Annual Scientific Meeting

Advanced Instruments launches novel GloCyte System at 68th AACC Annual Scientific Meeting

Advanced Instruments, Inc., a leader in laboratory instrumentation, launches their GloCyte Automated Cell Counter System at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, PA July 31-August 4. [More]
T-cell technology could be used to treat ovarian tumors with no adverse effects

T-cell technology could be used to treat ovarian tumors with no adverse effects

With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive. [More]
Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease. [More]
Researchers develop new test for early detection of patients' resistance to leukemia treatment

Researchers develop new test for early detection of patients' resistance to leukemia treatment

Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia. [More]
Umbilical CBT more effective than MUD bone marrow transplants for leukemia patients

Umbilical CBT more effective than MUD bone marrow transplants for leukemia patients

A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009-2014, finding that three years post transplant, the incidence of severe chronic graft-versus-host disease was 44 percent in patients who had received transplants from matched, unrelated donors (MUD) and 8 percent in patients who had received umbilical cord blood transplants (CBT). [More]
Scientists identify new genetic variations contributing to onset of APL

Scientists identify new genetic variations contributing to onset of APL

A study led by a team of scientists from the Cancer Science Institute of Singapore at the National University of Singapore has identified new genetic alterations contributing to the onset of Acute Promyelocytic Leukemia (APL). [More]
Advertisement
Advertisement